Alnylam Pharmaceuticals this week announced that the European Patent Office has said it intends to grant it a patent broadly covering RNAi therapeutics.
The patent is assigned to the Max Planck Society, the Massachusetts Institute of Technology, and the Whitehead Institute for Biomedical Research and exclusively licensed by Alnylam.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
